Trinity Biotech Gains Final Approval for Offshore HIV Test Production
Event summary
- Trinity Biotech received final regulatory approval on February 10, 2026 to begin upstream manufacturing of its Uni-Gold™ HIV rapid test under an offshored and outsourced model.
- The approval marks the last major regulatory milestone for Trinity Biotech's new production model, following WHO authorization in November 2025.
- The company expects the shift to improve gross margins, working capital efficiency, and long-term scalability.
- This transition is part of Trinity Biotech's Comprehensive Transformation Plan.
The big picture
Trinity Biotech's shift to an offshored and outsourced manufacturing model for its Uni-Gold™ HIV rapid test aligns with broader industry trends toward cost-efficient production and global scalability. This strategic move is part of the company's broader transformation plan, which includes expanding into wearable biosensors through its acquisition of Waveform Technologies Inc. The approval positions Trinity Biotech to better compete in the global HIV rapid testing market while improving its financial profile.
What we're watching
- Margin Expansion
- How the offshore production model will affect Trinity Biotech's gross margins and whether these gains will be sustainable.
- Scalability Challenges
- The pace at which Trinity Biotech can scale production to meet global HIV testing demand.
- Regulatory Compliance
- Whether the company can maintain compliance with both WHO and in-country regulations as it expands its offshore operations.
Related topics